Therapeutic plasma exchange combined with intravenous immunoglobulin reduced biological age on average by 2.6 years, as ...

The FDA cleared an investigational new drug application for a phase 2 trial of GRF312 ophthalmic solution, an immunoglobulin ...

Due to the autoimmune etiology of this disorder, IV immunoglobulin (IVIg) or plasma exchange (PE) are the first-line treatments in addition to management of ventilatory failure. IVIg is more ...

"Nuvig Therapeutics begins dosing in trial of NVG-2089 for CIDP" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this s ...

The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for sibeprenlimab for the treatment of immunoglobulin A nephropathy (IgAN) in adults.

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

By binding and inhibiting APRIL, sibeprenlimab may help reduce the amount of immunoglobulin A (IgA) and Gd-IgA1 levels. Lower levels of Gd-IgA1 provide less substrate for immune complex formation ...

Selagine, Inc., a spin-out company from the University of Illinois Chicago (UIC), announced today that the U.S. Food and Drug ...

The following is a summary of “Predicting intrathecal immunoglobulin synthesis in the ICU: a comparative study of IgG-based indexes,” published in the April 2025 issue of Annals of Intensive Care by ...

NICE reversed its earlier decision on sparsentan for treating primary immunoglobulin A nephropathy after additional evidence ...

Atrasentan reduced urine protein-to-creatinine ratio by 38% compared with 3% for placebo at week 36. The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia ...

Katherine Wells, director of public health in Lubbock, Texas, said in a briefing Tuesday that “very young babies” who were exposed to measles have needed immunoglobulin injections, antibodies ...